Assessing Kidney Function

Pierre Delanaye, Andrew D Rule

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Kidney function is largely defined by GFR. Using GFR to characterize CKD requires an understanding of its physiological variation as well as its decline with healthy aging. The measurement of GFR is based on the urinary or plasma clearance of an ideal or near ideal exogenous marker such as inulin or iothalamate. This requires infrastructure, expense, and patient burden that are not feasible in most clinical settings. Endogenous markers cleared primarily by glomerular filtration, particularly serum creatinine, are more practical and useful to detect loss of kidney function. Estimated GFR can improve the interpretation and application of endogenous filtration markers as GFR. However, estimated GFR still reflects non-GFR biology of the underlying markers. There is not one GFR estimating equation that accurately estimates GFR in all clinical settings, optimally predicts CKD outcomes, and performs the same as measured GFR in its association with CKD risk factors and outcomes.

Original languageEnglish (US)
Title of host publicationChronic Renal Disease
PublisherElsevier Inc.
Pages31-42
Number of pages12
ISBN (Print)9780124116160, 9780124116023
DOIs
StatePublished - Sep 24 2014

Fingerprint

Iothalamic Acid
Kidney
Inulin
Creatinine
Serum

Keywords

  • Aging kidney
  • Creatinine
  • Cystatin C
  • Glomerular filtration rate
  • Inulin clearance
  • Iothalamate clearance
  • Kidney function

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Delanaye, P., & Rule, A. D. (2014). Assessing Kidney Function. In Chronic Renal Disease (pp. 31-42). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-411602-3.00004-4

Assessing Kidney Function. / Delanaye, Pierre; Rule, Andrew D.

Chronic Renal Disease. Elsevier Inc., 2014. p. 31-42.

Research output: Chapter in Book/Report/Conference proceedingChapter

Delanaye, P & Rule, AD 2014, Assessing Kidney Function. in Chronic Renal Disease. Elsevier Inc., pp. 31-42. https://doi.org/10.1016/B978-0-12-411602-3.00004-4
Delanaye P, Rule AD. Assessing Kidney Function. In Chronic Renal Disease. Elsevier Inc. 2014. p. 31-42 https://doi.org/10.1016/B978-0-12-411602-3.00004-4
Delanaye, Pierre ; Rule, Andrew D. / Assessing Kidney Function. Chronic Renal Disease. Elsevier Inc., 2014. pp. 31-42
@inbook{bc39d988f18744e497457accd5cabdd6,
title = "Assessing Kidney Function",
abstract = "Kidney function is largely defined by GFR. Using GFR to characterize CKD requires an understanding of its physiological variation as well as its decline with healthy aging. The measurement of GFR is based on the urinary or plasma clearance of an ideal or near ideal exogenous marker such as inulin or iothalamate. This requires infrastructure, expense, and patient burden that are not feasible in most clinical settings. Endogenous markers cleared primarily by glomerular filtration, particularly serum creatinine, are more practical and useful to detect loss of kidney function. Estimated GFR can improve the interpretation and application of endogenous filtration markers as GFR. However, estimated GFR still reflects non-GFR biology of the underlying markers. There is not one GFR estimating equation that accurately estimates GFR in all clinical settings, optimally predicts CKD outcomes, and performs the same as measured GFR in its association with CKD risk factors and outcomes.",
keywords = "Aging kidney, Creatinine, Cystatin C, Glomerular filtration rate, Inulin clearance, Iothalamate clearance, Kidney function",
author = "Pierre Delanaye and Rule, {Andrew D}",
year = "2014",
month = "9",
day = "24",
doi = "10.1016/B978-0-12-411602-3.00004-4",
language = "English (US)",
isbn = "9780124116160",
pages = "31--42",
booktitle = "Chronic Renal Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Assessing Kidney Function

AU - Delanaye, Pierre

AU - Rule, Andrew D

PY - 2014/9/24

Y1 - 2014/9/24

N2 - Kidney function is largely defined by GFR. Using GFR to characterize CKD requires an understanding of its physiological variation as well as its decline with healthy aging. The measurement of GFR is based on the urinary or plasma clearance of an ideal or near ideal exogenous marker such as inulin or iothalamate. This requires infrastructure, expense, and patient burden that are not feasible in most clinical settings. Endogenous markers cleared primarily by glomerular filtration, particularly serum creatinine, are more practical and useful to detect loss of kidney function. Estimated GFR can improve the interpretation and application of endogenous filtration markers as GFR. However, estimated GFR still reflects non-GFR biology of the underlying markers. There is not one GFR estimating equation that accurately estimates GFR in all clinical settings, optimally predicts CKD outcomes, and performs the same as measured GFR in its association with CKD risk factors and outcomes.

AB - Kidney function is largely defined by GFR. Using GFR to characterize CKD requires an understanding of its physiological variation as well as its decline with healthy aging. The measurement of GFR is based on the urinary or plasma clearance of an ideal or near ideal exogenous marker such as inulin or iothalamate. This requires infrastructure, expense, and patient burden that are not feasible in most clinical settings. Endogenous markers cleared primarily by glomerular filtration, particularly serum creatinine, are more practical and useful to detect loss of kidney function. Estimated GFR can improve the interpretation and application of endogenous filtration markers as GFR. However, estimated GFR still reflects non-GFR biology of the underlying markers. There is not one GFR estimating equation that accurately estimates GFR in all clinical settings, optimally predicts CKD outcomes, and performs the same as measured GFR in its association with CKD risk factors and outcomes.

KW - Aging kidney

KW - Creatinine

KW - Cystatin C

KW - Glomerular filtration rate

KW - Inulin clearance

KW - Iothalamate clearance

KW - Kidney function

UR - http://www.scopus.com/inward/record.url?scp=84946005679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946005679&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-411602-3.00004-4

DO - 10.1016/B978-0-12-411602-3.00004-4

M3 - Chapter

SN - 9780124116160

SN - 9780124116023

SP - 31

EP - 42

BT - Chronic Renal Disease

PB - Elsevier Inc.

ER -